Efficiency of complex therapy in patients with a- and hypogammaglobulinemia

Abstract

Objective: assessment of the effectiveness of the use of Polymuramil in complex with IVG therapy with patients with CVID and ХLA with insufcient replacement therapy.Materials and methods: there were 10 patients with insufcient effectiveness of IVIG replacement therapy, receiving complex IVIG therapy and immunomodulator Polymuramil at a dose of 200 μg / 0.5 ml No. 5 intramuscularly every other day, under study. Surface and intracellular markers of cells of the congenital and acquired immune response, serum immunoglobulins of class A, M, G - in the radial immunodiffusion in the Mancini gel, the oxygen-dependent metabolic activity of neutrophils in NST-test were assessed with the help of flow cytometry, before and afer 3 months and a comparative analysis of the obtained data was conducted.Results: analysis of the data revealed a signifcant increase in markers of lymphocyte activation, which indicates the induction properties of the studied immunomodulator by increasing the activation potentials of the cellular link of adaptive immunity in patients with primary immunodefciency.Summary: in patients with a genetically mediated defect of the humoral immunity against the background of complex therapy with the use of Polymuramil, the activation of congenital and adaptive immunity is registered, which is confrmed, in addition to laboratory indexes, by a decrease in the frequency of exacerbations of chronic inflammatory diseases.

Keywords

• a-(hypo)gammaglobulinemia
• primary immunodeficiency
• immunomodulatory
• cellular immunity